药明合联:全球ADC/XDC一体化服务龙头 商业化蓄势待发

东方证券
22 hours ago

全球ADC 与生物偶联药CRDMO 领导者。公司是专注于ADC 及更广泛XDC 的全球领先CRDMO,据沙利文测算,2022 年公司全球市占率达9.8%,位居全球第二、国内第一。受益于前两大股东药明生物和药明康德在大小分子CRDMO 上的技术、人才和产能积累,公司业绩高速增长:2020-2023 年营收和归母净利润CAGR分别为180%和121%,24 年分别同比增长91%和277%。净利润加速...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10